- Existing investors, ClavystBio and Invus participated in the & nbsp, round
- Funds will aid in advancing biomarkers, target discoveries through collaboration & nbsp,
Engine Biosciences, a company leveraging machine learning and high – throughput biology to discover and develop precision oncology medicines has announced the completion of a US$ 27 million( RM125.5 million ) Series A extension. The financing was led by Polaris Partners, with participation from both new and existing investors, bringing the total funds raised since inception to US$ 86 million( RM399.9 million ). & nbsp,
In a statement, the company that was founded in 2014 in San Francisco and is now based in Singapore & nbsp, said additional participating investors include existing investors ClavystBio( a life sciences venture investor set up by Temasek ), Invus, and Singapore – based global investor EDBI, as well as new investors Coronet Ventures( a Singapore – based investment entity of Cedars Sinai Intellectual Property Company ) and SEEDS Capital( investment arm of Enterprise Singapore ). & nbsp,
It added that in conjunction with the funding, Wen Qi Ho Ph. D., Therapeutics result at ClavystBio, has joined Engine’s Board of Directors.
Engine’s precision medicine R & amp, D platform deciphers biological networks and pinpoints key genetic interactions driving diseases, overcoming challenges presented by biological complexity. These insight reveal goals and therapeutics to be used in diagnostic – defined individual populations, allowing for more rapid identification of successful detail medicines. & nbsp,
In cancer, Engine leverages the validated principle of chemical mortality and is focused on the scientific language of therapeutics and biomarkers across solid tumours, including cervical, colorectal, liver, lung and prostate cancers. & nbsp,
Jeffrey Lu ( pic ), Engine Biosciences ‘ co – founder and CEO stated that the company’s findings support Engine’s mission to,” deliver clinical impact through directing the right drug for the right target to the right patient”.
To date, Engine has revealed over thirty previously unidentified detail medicine opportunities with verification data, anchoring its network and giving partnerships. Its interior drug finding biology and chemistry teams have progressed several programs considerably from initial identification. & nbsp,
Among its oncology pipeline is ENB – 812, which Engine has overseen from freely discovering PKMYT1 as a chemical destructive target with fascinating biomarkers in 2019, generating preliminary proof – of – concept across several tumour types and animal models, observing friendly clinical data, and advancing lead identification and optimisation.
In addition to great – price targets and medicine candidates, Engine identified new patient collection biomarkers for various different classes of targeted therapies. According to the company, its indicators have been proven 100 times to make tumors more sensitive to particular clinical-stage experimental drugs. It stated that these biomarkers have the potential to improve clinical outcomes, expand commercial potential, and strengthen drug development economics in the near future.
According to Amy Schulman, managing partner of Polaris Partners, the business has seen first-hand Engine make significant advancements since making its first purchase, moving their technologies in the direction of compelling accuracy medicines ready for translation.
She continued,” We are leading this powerful investor consortium in support of Engine’s achievement of therapeutic value creation through the creation of its therapies, indicators, and alliances.”
The proprietary platforms of Engine, NetMAPPR ( machine learning-enabled network biology ) and CombiGEM( combinatorial genetics experimentation ), are designed for drug hunters and clinical developers to find and optimize precision medicines. These platforms are the result of years of research and development at its Singapore and Silicon Valley sites, as well as foundational science from MIT, UCSF, University of California, and Mayo Clinic. Engine’s broad biology understanding and datasets offer insights on desired target product profile characteristics, guiding the design and optimization of best-in-class therapeutics, in addition to high-value targets with associated biomarker-defined patient populations.
Wen Qi Ho, Ph., stated that he and a powerful family of existence sciences investors are dedicated to assisting Engine’s expansion as an international biotech company. D., ClavystBio, Therapeutics result. This is in line with our goal of establishing businesses in Singapore that take advantage of global access to skill, data, and therapeutic opportunities as well as translating research into actual medical impact.
The platforms and programs of Engine are supported by a sizable trademark investment. Through internal advancement, partnerships, and collaborations, the company will use the extra funds to expand its biomarker and targeted discoveries toward the clinic.
According to Nirdesh Gupta, Ph.,” Precision medication holds the key to the next wave of ground-breaking treatments, and it tightly connects Coronet Ventures with Engine’s mission.” D., the head of Coronet Ventures. ” Investing in the business reflects our dedication to launching globally successful ventures in Singapore and bringing scientific research advances to completion.”